| scholarly article | Q13442814 |
| P50 | author | Elvira Pelosi | Q57305950 |
| P2093 | author name string | Germana Castelli | |
| Ugo Testa | |||
| P2860 | cites work | Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 |
| Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma | Q27852915 | ||
| Unique genomic profile of fibrolamellar hepatocellular carcinoma | Q27853116 | ||
| DNAJB1-PRKACA is specific for fibrolamellar carcinoma. | Q27853135 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma | Q28072292 | ||
| Genetic alterations in hepatocellular carcinoma: An update | Q28073241 | ||
| Long-term culture of genome-stable bipotent stem cells from adult human liver | Q28254408 | ||
| Elevated expression of Wnt antagonists is a common event in hepatoblastomas | Q28256831 | ||
| Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma | Q28257545 | ||
| Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. | Q40151513 | ||
| CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity | Q40186273 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties | Q40262786 | ||
| Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas | Q40493289 | ||
| Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups | Q40519988 | ||
| Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas | Q40613665 | ||
| Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. | Q40720624 | ||
| Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells | Q40971187 | ||
| Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma | Q40987028 | ||
| Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. | Q41536211 | ||
| Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy | Q41547474 | ||
| Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis | Q41561467 | ||
| The CD133+CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma. | Q41871003 | ||
| Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma | Q41966267 | ||
| Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells | Q42090033 | ||
| Trans-ancestry mutational landscape of hepatocellular carcinoma genomes | Q42182370 | ||
| Intratumor heterogeneity in hepatocellular carcinoma | Q42186312 | ||
| The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma | Q42271559 | ||
| p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells | Q42716243 | ||
| Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma | Q42811795 | ||
| Molecular classification of hepatocellular carcinoma: potential therapeutic implications | Q43059019 | ||
| Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma | Q43238565 | ||
| Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers | Q45704144 | ||
| Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. | Q46688979 | ||
| Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. | Q47199334 | ||
| Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways | Q47624575 | ||
| Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. | Q47829403 | ||
| A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer | Q48225584 | ||
| A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells | Q50115050 | ||
| Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management | Q50242982 | ||
| Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line | Q38765553 | ||
| lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal | Q38767528 | ||
| Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification | Q38770158 | ||
| Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer | Q38775165 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. | Q38826826 | ||
| Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma | Q38893550 | ||
| Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. | Q38901483 | ||
| WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited | Q38908764 | ||
| Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma | Q38917883 | ||
| Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma | Q38947320 | ||
| The genomic landscape of hepatoblastoma and their progenies with HCC-like features | Q38964756 | ||
| β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma | Q38993024 | ||
| Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity | Q38996780 | ||
| Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation | Q39003817 | ||
| Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. | Q39065107 | ||
| Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation | Q39113102 | ||
| 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit. | Q39164056 | ||
| CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells | Q39227532 | ||
| Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma | Q39240497 | ||
| Mechanisms of hepatic stellate cell activation | Q39294420 | ||
| OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma | Q39345207 | ||
| Molecular Pathogenesis of Liver Cancer | Q39440917 | ||
| CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma | Q39443999 | ||
| CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling | Q39459026 | ||
| Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon | Q39481868 | ||
| CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation | Q39512947 | ||
| miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. | Q39626637 | ||
| Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma | Q39720613 | ||
| Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma | Q39807521 | ||
| An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. | Q39850331 | ||
| Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells | Q39976254 | ||
| EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma | Q40006245 | ||
| CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. | Q40076996 | ||
| Identification and characterization of tumorigenic liver cancer stem/progenitor cells | Q40119609 | ||
| Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies | Q40131537 | ||
| Significance of CD90+ cancer stem cells in human liver cancer | Q28266933 | ||
| Oncofetal gene SALL4 in aggressive hepatocellular carcinoma | Q28292533 | ||
| Gene expression profiling of liver cancer stem cells by RNA-sequencing | Q28483663 | ||
| EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features | Q30493364 | ||
| CD13 is a therapeutic target in human liver cancer stem cells | Q30496324 | ||
| Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles | Q32173000 | ||
| Characterization of a side population of cancer cells from human gastrointestinal system | Q33225639 | ||
| Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas | Q33581027 | ||
| Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells | Q33617469 | ||
| Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation | Q33652971 | ||
| Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis | Q33716459 | ||
| Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups | Q33757122 | ||
| Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma | Q33820376 | ||
| Clonal tracing of Sox9+ liver progenitors in mouse oval cell injury | Q33831544 | ||
| Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis | Q33851416 | ||
| Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma | Q33888432 | ||
| Hippo pathway activity influences liver cell fate | Q34060093 | ||
| Patient-derived xenograft models: an emerging platform for translational cancer research | Q34205518 | ||
| Gene expression in fixed tissues and outcome in hepatocellular carcinoma. | Q34235518 | ||
| p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer | Q34457367 | ||
| The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients. | Q34458870 | ||
| Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? | Q34562989 | ||
| Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes | Q34623312 | ||
| Genomic analysis of fibrolamellar hepatocellular carcinoma | Q34673400 | ||
| Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. | Q34798776 | ||
| Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells | Q35100733 | ||
| Hepatic stellate cells contribute to progenitor cells and liver regeneration | Q35145385 | ||
| Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury | Q35223537 | ||
| Contribution of Mature Hepatocytes to Biliary Regeneration in Rats with Acute and Chronic Biliary Injury | Q35755696 | ||
| Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | Q35842729 | ||
| Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. | Q35861861 | ||
| Liver cancer: Approaching a personalized care | Q35903794 | ||
| The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers | Q35958822 | ||
| A critical role for notch signaling in the formation of cholangiocellular carcinomas | Q50945875 | ||
| Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity | Q50967175 | ||
| Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. | Q52580893 | ||
| Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. | Q52757804 | ||
| Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. | Q52764639 | ||
| Sox9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma. | Q52883380 | ||
| Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma. | Q53130903 | ||
| Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. | Q53232555 | ||
| Genomic spectra of biliary tract cancer. | Q53390123 | ||
| Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. | Q53391138 | ||
| Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. | Q54346071 | ||
| Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer | Q56762983 | ||
| Hepatocytes, rather than cholangiocytes, can be the major source of primitive ductules in the chronically injured mouse liver | Q57152504 | ||
| Hepatocellular carcinoma | Q57756376 | ||
| A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection | Q57756525 | ||
| Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin | Q73773421 | ||
| Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells | Q79348140 | ||
| Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma | Q81275056 | ||
| EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma | Q82226524 | ||
| CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma | Q84059678 | ||
| Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation | Q84285518 | ||
| Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells | Q85651114 | ||
| Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells | Q86199507 | ||
| Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. | Q37719254 | ||
| EpCAM and its potential role in tumor-initiating cells | Q38014664 | ||
| Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis | Q38088149 | ||
| Differentiation of progenitors in the liver: a matter of local choice | Q38103361 | ||
| Exploration of liver cancer genomes | Q38182833 | ||
| Hydrodynamic transfection for generation of novel mouse models for liver cancer research | Q38183539 | ||
| Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. | Q38208965 | ||
| Sry HMG box protein 9-positive (Sox9+) epithelial cell adhesion molecule-negative (EpCAM-) biphenotypic cells derived from hepatocytes are involved in mouse liver regeneration. | Q38268256 | ||
| Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. | Q38311444 | ||
| Evidence of cell-fate conversion from hepatocytes to cholangiocytes in the injured liver: in-vivo genetic lineage-tracing approaches. | Q38375064 | ||
| The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling | Q38427302 | ||
| Advances in targeted therapies for hepatocellular carcinoma in the genomic era. | Q38521011 | ||
| TERT promoter mutations in primary liver tumors | Q38580138 | ||
| Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma | Q38592694 | ||
| Functional and genetic deconstruction of the cellular origin in liver cancer. | Q38614249 | ||
| Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features | Q38721035 | ||
| Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma | Q38722204 | ||
| Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition | Q38726399 | ||
| Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer | Q35985007 | ||
| Bile acids induce hepatic differentiation of mesenchymal stem cells | Q35993419 | ||
| Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. | Q36000076 | ||
| YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression | Q36048228 | ||
| SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis. | Q36084140 | ||
| Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | Q36104399 | ||
| Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver | Q36108383 | ||
| Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells | Q36145871 | ||
| ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells | Q36165630 | ||
| Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. | Q36165673 | ||
| CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells | Q36170883 | ||
| Hepatic progenitor cells of biliary origin with liver repopulation capacity | Q36181615 | ||
| Transcriptomic characterization of fibrolamellar hepatocellular carcinoma | Q36268536 | ||
| SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma | Q36413790 | ||
| Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma | Q36547263 | ||
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes | Q36759538 | ||
| Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. | Q36771967 | ||
| In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. | Q36791239 | ||
| Robust cellular reprogramming occurs spontaneously during liver regeneration. | Q36804095 | ||
| Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma | Q36891677 | ||
| Prognostic value of DNA repair based stratification of hepatocellular carcinoma | Q36903275 | ||
| A genomic case study of mixed fibrolamellar hepatocellular carcinoma | Q36935210 | ||
| The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma | Q36962663 | ||
| High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions | Q37064910 | ||
| Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. | Q37170296 | ||
| Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. | Q37190234 | ||
| MEK1 signaling promotes self-renewal and tumorigenicity of liver cancer stem cells via maintaining SIRT1 protein stabilization | Q37190384 | ||
| Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin | Q37316239 | ||
| Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target | Q37353061 | ||
| Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma | Q37408965 | ||
| LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. | Q37486949 | ||
| The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice | Q37526352 | ||
| Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. | Q37552414 | ||
| Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. | Q37619600 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P921 | main subject | liver cancer | Q623031 |
| neoplastic stem cells | Q1638475 | ||
| P577 | publication date | 2017-09-20 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells | |
| P478 | volume | 9 |
| Q57149088 | A Novel Method to Improve the Anticancer Activity of Natural-Based Hydroxyapatite against the Liver Cancer Cell Line HepG2 Using Mesoporous Magnesia as a Micro-Carrier |
| Q95839665 | APN-mediated phosphorylation of BCKDK promotes hepatocellular carcinoma metastasis and proliferation via the ERK signaling pathway |
| Q92841191 | Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis |
| Q90092754 | Aldehyde Dehydrogenase, Liver Disease and Cancer |
| Q60908233 | Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice |
| Q55223236 | Cancer stem cells of hepatocellular carcinoma. |
| Q91755702 | Cervical cancer stem cell-associated genes: Prognostic implications in cervical cancer |
| Q97093992 | Circular RNA Expression Profiles and the Pro-tumorigenic Function of CircRNA_10156 in Hepatitis B Virus-Related Liver Cancer |
| Q99629822 | Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis |
| Q64891768 | Exosomes derived from HBV-associated liver cancer promote chemoresistance by upregulating chaperone-mediated autophagy. |
| Q92617247 | Expression of CD44 and MDM2 in cholangiocarcinoma is correlated with poor clinicopathologic characteristics |
| Q57046983 | Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential |
| Q64075548 | Iron Metabolism in Liver Cancer Stem Cells |
| Q92820021 | Isovitexin reduces carcinogenicity and stemness in hepatic carcinoma stem-like cells by modulating MnSOD and FoxM1 |
| Q92875674 | Metastasis of Cancer Stem Cells Developed in the Microenvironment of Hepatocellular Carcinoma |
| Q64285369 | MicroRNA-1305 Inhibits the Stemness of LCSCs and Tumorigenesis by Repressing the UBE2T-Dependent Akt-Signaling Pathway |
| Q91865045 | Overexpression of miR-450 affects the biological behavior of HepG2 cells by targeting DNMT3a |
| Q92255501 | Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression |
| Q64114256 | Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib |
| Q54112713 | The SHH/Gli axis regulates CD90-mediated liver cancer stem cell function by activating the IL6/JAK2 pathway. |
| Q91621531 | Tumour evolution in hepatocellular carcinoma |
Search more.